viewBiocept Inc

Biocept announces commercial launch of its Target Selector panel to detect lung cancer; stock jumps

Physicians and researchers can use Target Selector to detect and monitor actionable biomarkers associated with lung cancer

Lung cancer is the leading cause of cancer death for both men and women in the US

Shares of Biocept Inc (NASDAQ:BIOC) rocketed by double-digits Monday after the supplier of liquid biopsy tests announced the commercial launch of its Target Selector NGS Lung Panel.

Biocept’s stock recently traded up 36% to $1.11 a share on higher-than-average volume.

According to a statement from the San Diego-based company, Target Selector is Biocept’s multi-gene liquid biopsy panel specifically developed for lung cancer and runs on Thermo Fisher Scientific Inc's (NYSE:TMO) Ion Torrent next generation sequencing (NGS) platform and will be marketed to physicians and researchers.

READ: Biocept prices $8.2M registered direct offering to institutional investors

The company said it can be used to detect and monitor actionable biomarkers associated with lung cancer, which is the leading cause of cancer death for both men and women in the US.

The panel combines Biocept's laboratory and commercial infrastructure, as well as the company's expertise in blood sample preservation and DNA/RNA isolation with Thermo Fisher's industry leading NGS panel and informatics technology branded as Oncomine, the statement said.

"We are very pleased to launch our first multi-gene liquid biopsy panel to physicians and researchers in both academic centers and the pharmaceutical industry," said Biocept CEO Michael Nall. "This new solution makes Biocept the only commercial liquid biopsy company that can offer customers the flexibility to order either a customized single biomarker assay or a larger NGS-based liquid biopsy test panel for use when more comprehensive testing is desired.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 0.974 USD

Market: NASDAQ
Market Cap: $127.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...



Full interview: Biocept receives CE-IVD Mark for Target Selector test kit...

Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE...

on 5/5/20

2 min read